Navigation Links
Analysis of FDA Adverse Events Data Reveals at Least 106 Serious Conditions Reported Among Reglan Users
Date:5/8/2009

An analysis of the Food and Drug Administration’s Adverse Event Reporting System has identified at least 106 cases of tardive dyskinesia or other movement disorders reported among users of Reglan or its generic version, metoclopramide. Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive movements of the extremities, including lip smacking, grimacing, tongue protrusion, rapid eye movements or blinking, puckering and pursing of the lips, or impaired movement of the fingers. These symptoms are rarely reversible and there is no known treatment.

(Vocus) May 8, 2009 -- An analysis of the Food and Drug Administration’s Adverse Event Reporting System has identified at least 106 cases of tardive dyskinesia or other movement disorders reported among users of Reglan or its generic version, metoclopramide.

Reglan and metoclopramide were approved by the FDA only for short-term treatment of certain gastrointestinal conditions, such as gastroesophageal reflux disease or diabetic gastroparesis. However, the manufacturers of these drugs derive substantial profit from their long-term use. The drugs work by speeding up the movement of the stomach muscles, which helps to increase the rate at which food moves from the stomach to the intestines.

In February 2009, the FDA forced the manufacturers of Reglan and metoclopramide to add a “black-box” warning to their labels about the strong connection between tardive dyskinesia and the long-term use of Reglan. Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive movements of the extremities, including lip smacking, grimacing, tongue protrusion, rapid eye movements or blinking, puckering and pursing of the lips, or impaired movement of the fingers. These symptoms are rarely reversible and there is no known treatment.

Because the risk of tardive dyskinesia may be greatest in patients who have taken Reglan or metoclopramide for an extended period, the FDA required a warning stating that chronic use of the drugs should be avoided, except in rare cases. According to the drug’s label, Reglan should only be prescribed for short-term use of four to 12 weeks. The safety of Reglan and metoclopramide use for longer than 12 weeks has not been studied.

“Tardive dyskinesia is a debilitating disease which substantially alters the quality of one’s life. It may affect thousands who used Reglan or metoclopramide,” says Shamus B. Mulderig, Managing Attorney of the Pharmaceutical and Medical Device Litigation Department at Hissey Kientz, LLP. “Tardive dyskinesia is a horrible affliction, is not reversible and has no cure. And because the FDA’s Adverse Event Reporting System is a voluntary reporting system, the number of reports received so far may seriously understate how widespread this affliction may be.”

Reglan is also linked to a serious and potentially fatal syndrome known as Neuroleptic Malignant Syndrome (NMS). Symptoms of NMS include hyperthermia, muscle rigidity, altered consciousness, irregular pulse, blood pressure or heartbeat or other symptoms.

An analysis conducted by the FDA found that, at a minimum, 20% of patients taking the drugs did so for longer than the three month maximum set by the agency. Other studies have identified Reglan and metoclopramide as the single most common cause of drug-induced movement disorders, including tardive dyskinesia.

“In addition to forcing the manufacturers to place a black box warning on the labels of Reglan and metoclopramide, the FDA required these companies to conduct a risk evaluation and mitigation strategy to ensure that patients are provided with a medication guide that discusses the risks associated with these drugs,” says Mulderig. “Unfortunately, these measures taken by the understaffed and underfunded FDA come much too late for the individuals who have already developed tardive dyskinesia or NMS from the long-term use of Reglan.”

About Hissey Kientz, LLP
Hissey Kientz, LLP is currently accepting cases involving individuals who may have developed tardive dyskinesia after using Reglan, as well as those affected by mesothelioma, asbestosis or lung cancer as a result of asbestos exposure; the Ortho Evra patch; digoxin toxicity from Digitek; pulmonary hypertension caused by Fen-Phen; the Composix Kugel mesh hernia patch; renal failure caused by Trasylol; the Duragesic or fentanyl pain patch; Raptiva; FELA railroad injuries; gadolinium MRI contrast dyes or other defective drugs and devices. To learn more about the firm and other drug cases, visit Hissey Kientz, LLP (www.hkllp.com) or call toll-free at (866) 275-4454.

###

Read the full story at http://www.prweb.com/releases/2009/05/prweb2400674.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Webcast Alert: Release of Economic Analysis Revealing $734 Billion in Savings Produced by Using Generic Medicines in 1999 - 2008
2. New data analysis shows possible link between childhood obesity and allergies
3. STIX Market Research Celebrates Ten Years of Technology/Market Analysis, Custom Research, and Niche Publishing; Prepares New Growth Phase
4. Genetic analysis may predict risk of invasive bladder cancer
5. Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide
6. How Can We Improve Our Elementary School System? - Unique Market Research Analysis of the Subconscious of Parents
7. China Medical Technologies Announces Receipt of SFDA Quality Testing Certificate for its SPR-based Analysis System
8. CDC analysis finds unique social and behavior intervention helps reduce MRSA rates up to 62 percent
9. Edifecs Announces New Version of Its Integrated HIPAA 5010 and ICD-10 Analysis and Migration Solution
10. An even-handed analysis of environmental policy
11. New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Analysis of FDA Adverse Events Data Reveals at Least 106 Serious Conditions Reported Among Reglan Users
(Date:2/6/2016)... CA (PRWEB) , ... February 06, 2016 , ... With ... and easily add warm color grades to their footage. A LUT is a Lookup ... pixel's color to the corresponding color indicated by the table. By manipulating each pixel, ...
(Date:2/5/2016)... Bethpage, NY (PRWEB) , ... February 05, 2016 , ... ... florist-quality long-stem roses in a variety of colors, assortments and packaging. This staple for ... at any King Kullen location. , For Valentine’s Day, not only are long-stem ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held on April 7, ... Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care ... with Parkinson’s disease and is the architect of this informative event to raise awareness ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President ... have signed a joint enrollment and degree completion agreement. The agreement, which ... baccalaureate degrees at FHU|Dickson. , The agreement allows students to be jointly ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... independent PROSHRED franchises from across the country gathered at the La Valencia Hotel ... top performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Feb. 5, 2016  ivWatch, a medical devices company, is ... Award granted by Governor Terry McAuliffe,s office. ivWatch ... February 25th at an event to be held at the ... award honors professionals and business that have made significant contributions ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> Research ...
(Date:2/5/2016)... , Feb. 5, 2016 Dehaier Medical ... or the "Company"), which develops, markets and sells ... China and international markets, ... which aims to concentrate the Company,s resources to ... respiratory business and to focus more on its ...
Breaking Medicine Technology: